SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...
In a significant medical feat, Indian scientists have developed the first-in-human gene therapy using lentiviral vectors for ...
ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...
India has successfully conducted its first in-human gene therapy for hemophilia A, with patients experiencing no bleeding ...
Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal ...
BHUBANESWAR: In a significant medical breakthrough, India's first human gene therapy with a lentiviral vector for severe ...
In the groundbreaking study the researchers observed an annualised zero bleeding rate in all the five subjects enrolled with ...
ATLANTA, GA, USA I December 11, 2024 I Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral ...
Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, venous access ...
VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth ...
The “bottleneck” of current gene therapy approaches is the lack of an efficient gene delivery system. Retroviral vectors have been very useful for ex vivo gene delivery, but suffer two major ...
Current lentiviral vector systems (the third generation) generate virus particles using four plasmids and a producer cell line. The rationale behind four plasmids is to enhance safety, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback